The efficacy and side effects of Secukinumab

Secukinumab (Secukinumab) is a fully humanized monoclonal anti-IL-17A antibody. It is the first drug of its kind approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis. It is also approved for the treatment of active psoriatic arthritis and ankylosing spondylitis. Its clinical efficacy in plaque psoriasis has been well demonstrated in many phase II and phase III clinical trials.

The pharmacokinetics of secukinumab were initially evaluated in healthy volunteers by intravenous and subcutaneous administration. After a single subcutaneous administration (150 mg or 300 mg), peak drug concentration is reached 5-6 days after injection. After repeated monthly dosing, peak concentrations tripled and reached a steady state after 20 weeks. Similar to other IgG1 human monoclonal antibodies, the average bioavailability of subcutaneous secukinumab is 73%. Common side effects include oral herpes, runny nose, and diarrhea, and in clinical trials, rare cases of allergic reactions, serious infections, and some severe inflammatory bowel disease have emerged.

Secukinumab The original drug has been launched in China and has entered the scope of Class B medical insurance. However, domestic patients who can purchase this drug are limited to eligible patients with psoriasis and ankylosing spondylitis. Patients who are not eligible for medical insurance reimbursement can only purchase it at their own expense. The price of each box of 150mg/ML is about RMB 1,000. SecukinumabThe original drug has also been launched overseas. The specifications of the Turkish original versionThe price per box of 150mg/ML is about 1,500 yuan, and the European version is 150m. The price of each box of g/ML*2 is around RMB 15,000 (the price may fluctuate due to the exchange rate). The ingredients of foreign original drugs and domestic original drugs are basically the same. Currently, there are no generic secukinumab drugs on the market.